Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Clarity commences Cu-64/Cu-67 SAR-bisPSMA theranostic prostate cancer trial

prnasiaJuly 29, 2021

Tag: clarity , Prostate Cancer , SAR-bisPSMA

PharmaSources Customer Service